<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011377</article-id><article-id pub-id-type="publisher-id">ACM-38584</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_53843098.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  156例外阴癌临床特征与预后分析
  Clinical Features and Prognostic Factors of 156 Cases of Vulvar Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>丽臣</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>于</surname><given-names>风胜</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>文杰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>于</surname><given-names>啸</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>言奎</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院妇科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2499</fpage><lpage>2503</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：分析影响外阴癌预后的因素。方法：回顾性分析2008年6月至2016年6月于青岛大学附属医院就诊的156例外阴癌患者临床资料。结果：影响外阴癌预后的独立危险因素包括合并自身免疫性疾病、肿瘤浸润深度、腹股沟淋巴结转移。合并有自身免疫性疾病、浸润深度 &gt; 1 mm、腹股沟淋巴结转移阳性患者的5年生存率分别为49.4%、45.1%、37.0% (P &lt; 0.05)。结论：积极治疗自身免疫性疾病可帮助改善外阴癌预后，术前评估应明确肿瘤浸润深度与腹股沟淋巴结转移情况，来确定足够的手术范围或术后是否进行辅助放化疗。
    Objective: To explore the risks of vulvar carcinoma. Method: From June 2008 to June 2016, 156 patients with vulvar carcinoma from the Affiliated Hospital of Qingdao University were analyzed retrospectively. Result: The independent prognostic factors are: autoimmune disease, infiltration depth and lymph node metastasis. The 5 years survival rate of someone who had autoimmune disease, infiltration depth more than 1 mm, lymph node metastasis were 49.4%, 45.1%, 37.0% (P &lt; 0.05). Conclusion: Positive treatment of autoimmune diseases can improve the prognosis. Before the operation, we should certain the infliltration depth and lymph node metastasis to choose appropriate surgery, radiotherapy and chemotherapy. 
  
 
</p></abstract><kwd-group><kwd>外阴癌，临床特征，预后, Vulvar Cancer</kwd><kwd> Clinical Features</kwd><kwd> Prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：分析影响外阴癌预后的因素。方法：回顾性分析2008年6月至2016年6月于青岛大学附属医院就诊的156例外阴癌患者临床资料。结果：影响外阴癌预后的独立危险因素包括合并自身免疫性疾病、肿瘤浸润深度、腹股沟淋巴结转移。合并有自身免疫性疾病、浸润深度 &gt; 1 mm、腹股沟淋巴结转移阳性患者的5年生存率分别为49.4%、45.1%、37.0% (P &lt; 0.05)。结论：积极治疗自身免疫性疾病可帮助改善外阴癌预后，术前评估应明确肿瘤浸润深度与腹股沟淋巴结转移情况，来确定足够的手术范围或术后是否进行辅助放化疗。</p></sec><sec id="s2"><title>关键词</title><p>外阴癌，临床特征，预后</p></sec><sec id="s3"><title>Clinical Features and Prognostic Factors of 156 Cases of Vulvar Cancer</title><p>Lichen Zhang<sup>*</sup>, Fengsheng Yu, Wenjie Wang, Xiao Yu, Yankui Wang<sup>#</sup></p><p>Department of Gynecology, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/11-1571653x5_hanspub.png" /></p><p>Received: Oct. 16<sup>th</sup>, 2020; accepted: Nov. 6<sup>th</sup>, 2020; published: Nov. 13<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/11-1571653x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the risks of vulvar carcinoma. Method: From June 2008 to June 2016, 156 patients with vulvar carcinoma from the Affiliated Hospital of Qingdao University were analyzed retrospectively. Result: The independent prognostic factors are: autoimmune disease, infiltration depth and lymph node metastasis. The 5 years survival rate of someone who had autoimmune disease, infiltration depth more than 1 mm, lymph node metastasis were 49.4%, 45.1%, 37.0% (P &lt; 0.05). Conclusion: Positive treatment of autoimmune diseases can improve the prognosis. Before the operation, we should certain the infliltration depth and lymph node metastasis to choose appropriate surgery, radiotherapy and chemotherapy.</p><p>Keywords:Vulvar Cancer, Clinical Features, Prognosis</p><disp-formula id="hanspub.38584-formula3"><graphic xlink:href="//html.hanspub.org/file/11-1571653x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/11-1571653x8_hanspub.png" /> <img src="//html.hanspub.org/file/11-1571653x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>外阴癌在女性生殖系统恶性肿瘤中相对较少见，发病率约占3%~5%，外阴癌发病机制尚未明确，目前认为主要与病毒感染相关，例如人乳头瘤病毒(HPV)、人类免疫缺陷病毒(HIV)、单纯疱疹病毒(HSV) II型等病毒有关，而性传播疾病、吸烟、酗酒、肥胖、自身免疫性疾病、过早性生活也可能影响了外阴癌的发病率 [<xref ref-type="bibr" rid="hanspub.38584-ref1">1</xref>]。近年来大样本调查研究表明，外阴癌发病率逐渐上升，但5年生存率却在逐渐下降，外阴癌预后与多种因素相关，NCCN指南提出，影响外阴癌预后的主要因素包括肿瘤分期、分化、浸润深度、切缘是否阳性、治疗方式、淋巴结转移情况等 [<xref ref-type="bibr" rid="hanspub.38584-ref2">2</xref>]。本文回顾性分析青岛大学附属医院在2008年6月~2016年6月期间收治的156例外阴癌患者的临床资料，探讨影响外阴癌预后的因素。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>本研究回顾性统计2008年6月~2016年6月青岛大学附属医院收治的符合纳入标准的156例外阴癌患者的临床资料。纳入标准：① 所有外阴癌患者均为原发病灶，且未合并子宫内膜癌、卵巢癌等其他恶性疾病；② 临床病历资料完整、清晰，回顾性较强，能够完成随访；③ 患者为我院初治，无外阴部位手术史；④ 术后病理均确诊为外阴癌。排除标准：① 外阴癌为其他部位癌变的转移病灶；② 除外阴癌外还患有其他恶性疾病或影响生存治疗的严重疾病；③ 年纪较大难以完成随访，干扰疾病生存率。156例患者年龄分布在21~72岁，中位年龄47岁，平均年龄49.5岁。94.67%患者发病部位在大、小阴唇和阴蒂，少数累及阴道、尿道与肛门、直肠。患者的主诉大多为外阴瘙痒、疼痛，并可扪及大小不等的外阴肿物或硬结。I期36例 (23.1%)，II期70例 (44.9%)，III期34例 (21.8%)，IV期16例 (10.3%)。</p></sec><sec id="s6_2"><title>2.2. 随访</title><p>通过电话、门诊进行为期5~137个月的随访。随访截至2020年6月，死于外阴癌13例，死于其他原因4例，复发或远处转移41例，共存活患者139例。</p></sec><sec id="s6_3"><title>2.3. 统计学方法</title><p>本次研究中使用SPSS 25.0软件对156例外阴癌患者的临床资料进行统计学分析，绘制图表；Kaplan-Meier计算不同分组生存率；Cox回归模型对疾病的预后进行多因素分析，数据结果以P &lt; 0.05来判断差异有无统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 外阴癌预后单因素分析</title><p>156例患者根据肿瘤部位、大小、浸润深度、有无淋巴结转移以及患者自身情况，给予个体化治疗，其中有61例接受手术治疗；68例患者根据术后病理以及淋巴结转移情况，接受了术后补充放疗，其中有6例患者接受3~6个疗程的化疗；23例因发生了远处转移或自身情况较差难以耐受手术而接受放疗与化疗；有4例患者未诊治，其中有2例发生肺转移。将可能影响这156例患者预后的因素进行统计分析，单因素分析结果显示影响预后的因素见表1，影响因素为：肿瘤部位、合并自身免疫性疾病、BMI指数、肿瘤类型、肿瘤浸润深度、淋巴结转移、肿瘤分期、治疗方式(P &lt; 0.05)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Univariate Kaplan Meier survival analysis of 156 patients with vulvar carcinom</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >分类</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >5年生存率(%)</th><th align="center" valign="middle" >χ<sup>2</sup>值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >年龄</td><td align="center" valign="middle" >&lt;50</td><td align="center" valign="middle" >72</td><td align="center" valign="middle" >66.7%</td><td align="center" valign="middle" >0.108</td><td align="center" valign="middle" >0.742</td></tr><tr><td align="center" valign="middle" >≥50</td><td align="center" valign="middle" >84</td><td align="center" valign="middle" >65.5%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >肿瘤部位</td><td align="center" valign="middle" >中线型</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >78.7%</td><td align="center" valign="middle" >10.284</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >侧位型</td><td align="center" valign="middle" >81</td><td align="center" valign="middle" >54.3%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >合并自身免疫性疾病</td><td align="center" valign="middle" >有</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >49.4%</td><td align="center" valign="middle" >24.169</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >69</td><td align="center" valign="middle" >87.0%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >BMI指数</td><td align="center" valign="middle" >&lt;28</td><td align="center" valign="middle" >93</td><td align="center" valign="middle" >72.0%</td><td align="center" valign="middle" >4.346</td><td align="center" valign="middle" >0.037</td></tr><tr><td align="center" valign="middle" >≥28</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >57.1%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >肿瘤类型</td><td align="center" valign="middle" >鳞癌</td><td align="center" valign="middle" >122</td><td align="center" valign="middle" >70.5%</td><td align="center" valign="middle" >5.698</td><td align="center" valign="middle" >0.017</td></tr><tr><td align="center" valign="middle" >非鳞癌</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >50.0%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >肿瘤大小</td><td align="center" valign="middle" >≤2 cm</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >68.0%</td><td align="center" valign="middle" >0.219</td><td align="center" valign="middle" >0.640</td></tr><tr><td align="center" valign="middle" >&gt;2 cm</td><td align="center" valign="middle" >81</td><td align="center" valign="middle" >64.2%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >浸润深度</td><td align="center" valign="middle" >≤1 mm</td><td align="center" valign="middle" >85</td><td align="center" valign="middle" >83.5%</td><td align="center" valign="middle" >27.692</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >&gt;1 mm</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >45.1%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >脉管浸润</td><td align="center" valign="middle" >有</td><td align="center" valign="middle" >52</td><td align="center" valign="middle" >59.6%</td><td align="center" valign="middle" >1.656</td><td align="center" valign="middle" >0.198</td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >104</td><td align="center" valign="middle" >69.2%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="2"  >淋巴结转移</td><td align="center" valign="middle" >有</td><td align="center" valign="middle" >81</td><td align="center" valign="middle" >37.0%</td><td align="center" valign="middle" >66.387</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >无</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >97.3%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="3"  >分化程度</td><td align="center" valign="middle" >高分化</td><td align="center" valign="middle" >82</td><td align="center" valign="middle" >69.5%</td><td align="center" valign="middle" >0.591</td><td align="center" valign="middle" >0.744</td></tr><tr><td align="center" valign="middle" >中分化</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >62.5%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >低分化</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >61.5%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="4"  >肿瘤分期</td><td align="center" valign="middle" >I期</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >72.2%</td><td align="center" valign="middle" >8.73</td><td align="center" valign="middle" >0.033</td></tr><tr><td align="center" valign="middle" >II期</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >74.3%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >III期</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >50.0%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >IV期</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >50.0%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  rowspan="4"  >治疗方式</td><td align="center" valign="middle" >手术</td><td align="center" valign="middle" >61</td><td align="center" valign="middle" >65.6%</td><td align="center" valign="middle" >8.519</td><td align="center" valign="middle" >0.036</td></tr><tr><td align="center" valign="middle" >手术 + 放化疗</td><td align="center" valign="middle" >68</td><td align="center" valign="middle" >75.0%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >放化疗</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >47.8%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >未治疗</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >25.0%</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 156例外阴癌患者单因素Kaplan-Meier生存分析</p></sec><sec id="s7_2"><title>3.2. 外阴癌预后多因素分析</title><p>COX多因素分析结果显示独立危险因素有：合并自身免疫性疾病、浸润深度、淋巴结转移(见表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Multivariate COX survival analysis of 156 patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >B</th><th align="center" valign="middle" >SE</th><th align="center" valign="middle" >walds</th><th align="center" valign="middle" >P值</th><th align="center" valign="middle" >HR</th><th align="center" valign="middle" >HR的95%CI</th></tr></thead><tr><td align="center" valign="middle" >肿瘤部位</td><td align="center" valign="middle" >−0.171</td><td align="center" valign="middle" >0.333</td><td align="center" valign="middle" >0.263</td><td align="center" valign="middle" >0.608</td><td align="center" valign="middle" >0.843</td><td align="center" valign="middle" >0.439~1.619</td></tr><tr><td align="center" valign="middle" >合并自身免疫性疾病</td><td align="center" valign="middle" >0.834</td><td align="center" valign="middle" >0.396</td><td align="center" valign="middle" >4.437</td><td align="center" valign="middle" >0.035</td><td align="center" valign="middle" >2.301</td><td align="center" valign="middle" >1.06~4.998</td></tr><tr><td align="center" valign="middle" >BMI指数</td><td align="center" valign="middle" >0.032</td><td align="center" valign="middle" >0.318</td><td align="center" valign="middle" >0.010</td><td align="center" valign="middle" >0.921</td><td align="center" valign="middle" >1.032</td><td align="center" valign="middle" >0.553~1.927</td></tr><tr><td align="center" valign="middle" >浸润深度</td><td align="center" valign="middle" >−1.041</td><td align="center" valign="middle" >0.379</td><td align="center" valign="middle" >7.546</td><td align="center" valign="middle" >0.006</td><td align="center" valign="middle" >0.353</td><td align="center" valign="middle" >0.168~0.742</td></tr><tr><td align="center" valign="middle" >淋巴结转移</td><td align="center" valign="middle" >3.475</td><td align="center" valign="middle" >0.767</td><td align="center" valign="middle" >20.523</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >32.306</td><td align="center" valign="middle" >7.18~145.297</td></tr></tbody></table></table-wrap><p>表2. 156例患者多因素COX生存分析结果</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>外阴癌早期诊断困难，组织病理活检是主要诊断方法。由于外阴癌临床症状复杂且缺乏特异性，部位隐匿，患者就诊意愿并不强烈，极易被自我诊断为炎症、皮疹等良性疾病而延误就诊。多数患者就诊时已有5~20年的外阴不适病史，反复发作，本研究患者从首发症状到就诊时间在1~145个月，平均52个月，病程较长。本研究显示影响外阴癌预后的独立因素包括合并自身免疫性疾病、浸润深度、淋巴结转移。</p><sec id="s8_1"><title>4.1. 合并自身免疫性疾病与预后</title><p>本研究156例患者中合并自身免疫性疾病87例(糖尿病51例，甲状腺功能亢进11例，类风湿性关节炎3例，系统性红斑狼疮5例，肾小球肾炎2例)，5年生存率49.4%，预后较差(P &lt; 0.05)。研究认为，自身免疫性疾病患者的免疫耐受被破坏，从而产生大量自身抗体攻击病损部位，尤其是BP180、Th1细胞因子的激活，以及与HLA II类抗原基因组的正相关也增加了相关疾病的易感性，这些患者对于肿瘤细胞的清除与监视功能降低，一旦发生了免疫逃逸，则肿瘤细胞迅速增殖并迁移，预后较差 [<xref ref-type="bibr" rid="hanspub.38584-ref3">3</xref>]。正常情况下毛细血管周围存在大量T细胞，包括在免疫调节中发挥协同作用的CD45RO+T细胞和CD68+细胞，有学者认为二者的浸润程度与外阴癌分化程度成负相关，随着肿瘤恶性程度的增加，T细胞减少，免疫监视作用减弱，且可能分泌某种物质来抑制机体的免疫应答 [<xref ref-type="bibr" rid="hanspub.38584-ref4">4</xref>]。所以积极治疗自身免疫性疾病，提高免疫力可改善预后。</p></sec><sec id="s8_2"><title>4.2. 肿瘤浸润深度与预后</title><p>NCCN指南提出肿瘤浸润深度是影响外阴癌预后的重要因素，根据浸润深度来决定手术方式：病变浸润深度 ≤ 1 mm行局部扩大切除术，术后病理若证实病灶浸润深度 ≤ 1 mm，随访即可，若深度 &gt; 1 mm，需后续补充手术治疗；病灶浸润深度 &gt; 1 mm，则需根据病灶位置决定手术范围，进行局部广泛手术与淋巴结清扫。有研究认为，浸润深度 &gt; 3 mm，淋巴结转移风险增加26.7%，预后较差 [<xref ref-type="bibr" rid="hanspub.38584-ref5">5</xref>]。但也有人认为浸润深度 &gt; 2 mm是影响外阴癌预后的独立危险因素，尚无统一的标准 [<xref ref-type="bibr" rid="hanspub.38584-ref6">6</xref>]。本研究中肿瘤浸润深度 &gt; 1 mm患者5年生存率为45.1% (P &lt; 0.05)，是影响外阴癌预后的独立因素。</p></sec><sec id="s8_3"><title>4.3. 淋巴结转移与预后</title><p>外阴癌主要的转移途径为淋巴转移：腹股沟浅淋巴结、腹股沟深淋巴结、盆腔淋巴结、腹主动脉旁淋巴结、锁骨下淋巴结，若腹股沟淋巴结阴性，5年生存率为90%左右，若阳性，则生存率下降至50%~60% [<xref ref-type="bibr" rid="hanspub.38584-ref7">7</xref>]。本研究腹股沟淋巴结阳性患者5年生存率为37.0% (P &lt; 0.05)，预后较差，与报道相符。所以近年来腹股沟淋巴结的清扫仍作为改善外阴癌预后的重要治疗手段。鉴于清扫淋巴结的手术范围大，术后并发症较多，所以有学者认为可根据前哨淋巴结活检的结果来决定是否进行腹股沟淋巴结清扫 [<xref ref-type="bibr" rid="hanspub.38584-ref7">7</xref>]。但活检结果存在一部分假阴性，且缺乏足够的远期观察结果支持临床安全性，因此前哨淋巴结活检在术中的应用尚存在很大的争议 [<xref ref-type="bibr" rid="hanspub.38584-ref8">8</xref>]。近几年已放弃盆腔淋巴结的清扫，代以术后补充放疗。术式也从开放淋巴结清扫更多的改行腹腔镜下腹股沟淋巴结清扫。采用腹腔镜手术，缩小了腹股沟区切口长度，保留较多的皮下组织，缝合张力也有所减小，有较多的血运有利于伤口的愈合，术后皮肤感染、手术区域伤口愈合不良、裂开、周围皮肤坏死等并发症较开放性手术降低，也缩短了住院时间。研究报道，腹腔镜手术的电切、电凝有利于及时封闭淋巴管，术后可以持续放置负压引流，减少淋巴液渗出 [<xref ref-type="bibr" rid="hanspub.38584-ref9">9</xref>]。</p><p>综上，肿瘤浸润深度、腹股沟淋巴结转移情况、合并自身免疫性疾病是影响外阴癌预后的独立危险因素。积极治疗自身免疫性疾病可以改善预后。术前应完善相关辅助检查，明确肿瘤浸润深度与淋巴结转移情况，以确保足够的手术范围，若术后发现肿瘤浸润深度 &gt; 1 mm或腹股沟淋巴结阳性等高危因素，可考虑再次手术或者术后辅助放化疗。</p></sec></sec><sec id="s9"><title>文章引用</title><p>张丽臣,于风胜,王文杰,于 啸,王言奎. 156例外阴癌临床特征与预后分析Clinical Features and Prognostic Factors of 156 Cases of Vulvar Cancer[J]. 临床医学进展, 2020, 10(11): 2499-2503. https://doi.org/10.12677/ACM.2020.1011377</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38584-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Van de Nieuwenh, H.P., Bulten J., Hollema H., et al. (2011) Differentiated Vulvar Intraepithelial Neoplasia Is Often Found in Lesions, Previously Diagnosed as Lichen Sclerosus, Which Have Progressed to Vulvar Squamous Cell Carcinoma. Modern Pathology, 24, 297-305. &lt;br&gt;https://doi.org/10.1038/modpathol.2010.192</mixed-citation></ref><ref id="hanspub.38584-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">林仲秋, 谢玲玲, 林荣春. 《FIGO 2015妇癌报告》解读连载五——外阴癌诊治指南解读[J]. 中国实用妇科与产科杂志, 2016, 32 (1): 47-53.</mixed-citation></ref><ref id="hanspub.38584-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">GentiBio Inc. (2020) GentiBio Launches to Develop Engineered Regulatory T Cells for Autoimmune and Inflammatory Diseases. NewsRx Health &amp; Science, 965.</mixed-citation></ref><ref id="hanspub.38584-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">田大彤, 武昕. CD45RO+T细胞和CD68+细胞在外阴上皮内非瘤样病变和外阴癌中的浸润[J]. 中国免疫学杂志, 2008, 24(12): 1094-1099.</mixed-citation></ref><ref id="hanspub.38584-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Le, S.T., Karia, P.S., Vollenhoven, B.J., et al. (2018) Evaluation of AJCC and an Alternative Tumor Classification System for Primary Vulvar Squamous Cell Carcinoma. Journal of the National Comprehensive Cancer Network, 16, 42-49. &lt;br&gt;https://doi.org/10.6004/jnccn.2017.7022</mixed-citation></ref><ref id="hanspub.38584-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Zanvettor, P.H., Filho, D.F., Soares, F.A., et al. (2014) Study of Biomolecular and Clinical Prognostic Factors in Patients with Cancer of the Vulva Undergoing Surgical Treatment. International Journal of Gynecological Cancer, 24, 766-772. &lt;br&gt;https://doi.org/10.1097/IGC.0000000000000103</mixed-citation></ref><ref id="hanspub.38584-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Drews, F., Lim, K.C.K. and Howells, R.E.J. (2016) A Study of Patients Treated for Primary Squamous Cell Carcinoma of the Vulva in the Regional Cancer Centre in Cardiff, UK. Acta Medica International, 3, 39-45.  
&lt;br&gt;https://doi.org/10.5530/ami.2016.1.10</mixed-citation></ref><ref id="hanspub.38584-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Euscher, E.D. and Malpica, A. (2020) Gynaecological Malignancies and Sentinel Lymph Node Mapping: An Update. Histopathology, 76, 139-150. &lt;br&gt;https://doi.org/10.1111/his.14017</mixed-citation></ref><ref id="hanspub.38584-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">刘钗娥, 卢艳. 外阴癌腹腔镜下腹股沟淋巴结清扫术的研究进展[J]. 临床肿瘤学杂志, 2016, 21(8): 760-763.</mixed-citation></ref></ref-list></back></article>